Drug intelligence / Profile preview

PHAGERIARUS

Development stage: Preclinical
Lead developer: iNtRON Biotechnology
Modality: Recombinant Proteins and Enzymes

Overview

PHAGERIARUS is a first-in-concept development project by iNtRON Biotechnology focused on bacteriophage-based immunotherapeutics. The platform utilizes bacteriophage-derived proteins, identified through genomic and functional analysis of disease-associated microbiomes (including prophages and jamphages), to act as immune regulators. These proteins are designed to suppress immune disorders and serve as anti-cancer immunotherapy. Initial development targets colorectal and pancreatic cancers, with potential expansion into microbiome-related neurological conditions such as Alzheimer's and Parkinson's diseases.

Beyond the preview

Go deeper on PHAGERIARUS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHAGERIARUS.

Explore the full profile